Discovery Mining (DSVSF) has been upgraded to a Buy rating due to its strong operational progress, including record revenues and a large silver reserve in Mexico. The company also made a strategic acquisition to diversify into base metals, aiming to triple production within five years. Despite higher-than-average costs per ounce and sector volatility, its stock has shown impressive performance, with a 934% dividend-adjusted gain over three years, ranking it 6th on the TSX30. This upgrade reflects confidence in its growth potential and sector outperformance.
Discovery Mining Ltd offers context for readers tracking Basic Materials. For readers following this sector, here is Pluang's market snapshot as of Oct 13, 2026 20:11 WIB: 38 of 62 US Basic Materials stocks rose today, 22 fell. Notable movers include PPG at USD 104.96 (+1.21%, typical hold time 68 days), GGB at USD 5.20 (+1.17%, typical hold time 4 days), and ALB at USD 97.40 (-1.13%, typical hold time 51 days, Pluang order activity 87% Sell / 13% Buy).
Domino's Pizza reported Q3 2026 earnings per share of $4.60, beating analyst expectations of $4.37, while revenue grew modestly by 3.4% to $1.19 billion. Same-store sales growth was minimal at 0.3% in the U.S. and 0.2% internationally, reflecting com...
Citigroup reported Q3 2026 earnings that exceeded analyst expectations, with EPS of $2.85 beating the $2.65 estimate and revenue of $23.8 billion slightly above forecasts. The bank's profit rose 40%, driven by exceptional fixed-income trading, invest...
State Street is set to report its Q3 2026 earnings with forecasts showing a 31.3% increase in earnings and 14% revenue growth, driven by strong net interest income and service fees. Despite record assets under management, higher operating and technol...
Restaurant Technologies, Inc. (RTI) released its 2026 Impact Report highlighting significant progress in sustainability and operational efficiency. In 2025, RTI recycled 393 million pounds of used cooking oil and delivered 719.4 million pounds of fre...
Over 60 companies are actively developing more than 65 medical marijuana therapies targeting conditions like chronic pain, neurological disorders, and cancer symptoms. Key drugs such as ZYN-002 and CardiolRx are in late-stage trials, with others in e...
